Free Trial

Talphera (TLPH) FDA Events

Talphera logo
$0.51 +0.00 (+0.60%)
As of 10:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
FDA Events for Talphera (TLPH)

This section highlights FDA-related milestones and regulatory updates for drugs developed by Talphera (TLPH). Over the past two years, Talphera has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Nafamostat. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

Nafamostat - FDA Regulatory Timeline and Events

Nafamostat is a drug developed by Talphera for the following indication: For Anticoagulation of the Extracorporeal Circuit. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Talphera FDA Events - Frequently Asked Questions

As of now, Talphera (TLPH) has not received any FDA approvals for its therapy in the last two years.

In the past two years, Talphera (TLPH) has reported FDA regulatory activity for Nafamostat.

The most recent FDA-related event for Talphera occurred on August 19, 2024, involving Nafamostat. The update was categorized as "Enrollment Update," with the company reporting: "Talphera, Inc. announced the first patient has been enrolled in the NEPHRO CRRT study."

Currently, Talphera has one therapy (Nafamostat) targeting the following condition: For Anticoagulation of the Extracorporeal Circuit.

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NASDAQ:TLPH) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners